Another case of jaundice for RG-101.
News & Analysis: Regulus Therapeutics
Achlllion Pharmaceuticals and Regulus Therapeutics have set their sights on the highly lucrative hepatitis C market.
Adverse events might sink the first candidate from an otherwise interesting platform.
Updated results for its clinical-stage hepatitis C drug failed to spark a rally.
A novel new hepatitis C drug under development at Regulus Therapeutics just put up impressive mid stage interim trial results.
The biopharma may have just hit pay dirt with its experimental hepatitis C treatment.
AstraZeneca Plc Inc is advancing Regulus Therapeutics' RG-125 into human trials.
Exciting but speculative -- Industry Focus examines two companies making strides in the treatment of hepatitis C.
AbbVie Inc and Gilead Sciences may want to consider Achillion Pharmaceuticals' and Regulus Therapeutics' intriguing hepatitis C drugs.
Here's why Ovascience, Bluebird Bio, and Regulus investors saw their share prices surge last quarter.